On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the September 2024 CRG meeting. Actions in this consultation include:
- Pylera (metronidazole / tetracycline / bismuth) – grey and green. See also separate consultation on Pylera position statement.
- H. pylori eradication – align formulary advice to BNF regiment
- Febuxostat for gout – green
- Abaloparatide for osteoporosis – RED
- Burosumab for X-linked hypophosphataemia – RED
- Relugolix for hormone-sensitive prostate cancer – AMBER
- Linzagolix for uterine fibroids – green (specialist advice)
- Risankizumab for ulcerative colitis – RED
- Hydrocortisone IM for adrenal crisis – green (specialist advice)
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Thursday 26th September 2024. To take part, visit the consultations page.